ABH antigenicity of in situ carcinoma of the urinary bladder during intracavity treatment with doxorubicin hydrochloride.
Ten patients with carcinoma in situ of the urinary bladder were treated topically with doxorubicin hydrochloride. Blood group antigens were evaluated by the specific red cell adherence tests. Carcinoma in situ was associated with the loss of antigenicity, the reappearance of which could be demonstrated in patients with tumour remission. This occurred in spite of a persistent nuclear atypia.
D000017:ABO Blood-Group System / Q000276:immunology*; D000368:Aged; D002278:Carcinoma in Situ / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D004317:Doxorubicin / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology
D000017:ABO Blood-Group System; D004317:Doxorubicin